Nisa Investment Advisors LLC Has $29,000 Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

Nisa Investment Advisors LLC raised its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) by 15,900.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,200 shares of the biotechnology company’s stock after acquiring an additional 3,180 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Avidity Biosciences were worth $29,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of RNA. Harbor Capital Advisors Inc. increased its holdings in Avidity Biosciences by 19.5% in the third quarter. Harbor Capital Advisors Inc. now owns 30,014 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 4,902 shares during the period. Raymond James & Associates grew its position in shares of Avidity Biosciences by 11.8% in the 3rd quarter. Raymond James & Associates now owns 93,255 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 9,815 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in shares of Avidity Biosciences by 33.4% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 34,772 shares of the biotechnology company’s stock valued at $222,000 after buying an additional 8,700 shares during the period. TD Asset Management Inc raised its position in shares of Avidity Biosciences by 100.0% during the third quarter. TD Asset Management Inc now owns 267,732 shares of the biotechnology company’s stock worth $1,708,000 after acquiring an additional 133,866 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in shares of Avidity Biosciences by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 66,220 shares of the biotechnology company’s stock worth $422,000 after acquiring an additional 31,277 shares during the period.

Analyst Ratings Changes

A number of research firms have weighed in on RNA. Cantor Fitzgerald began coverage on shares of Avidity Biosciences in a research report on Thursday, March 14th. They set an “overweight” rating and a $60.00 target price for the company. Wells Fargo & Company reiterated an “overweight” rating and set a $50.00 price objective on shares of Avidity Biosciences in a research report on Wednesday, January 3rd. Chardan Capital restated a “buy” rating and issued a $23.00 target price on shares of Avidity Biosciences in a report on Thursday, February 29th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $35.00 price objective on shares of Avidity Biosciences in a research report on Thursday, April 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Avidity Biosciences presently has an average rating of “Buy” and a consensus target price of $36.33.

Insider Buying and Selling at Avidity Biosciences

In other news, Director Arthur A. Levin sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, April 19th. The stock was sold at an average price of $22.82, for a total transaction of $114,100.00. Following the transaction, the director now directly owns 14,830 shares of the company’s stock, valued at $338,420.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Arthur A. Levin sold 20,000 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $27.11, for a total value of $542,200.00. Following the sale, the director now owns 253,872 shares in the company, valued at approximately $6,882,469.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Arthur A. Levin sold 5,000 shares of the firm’s stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $22.82, for a total transaction of $114,100.00. Following the completion of the transaction, the director now directly owns 14,830 shares in the company, valued at approximately $338,420.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 204,641 shares of company stock valued at $4,676,431. Company insiders own 2.00% of the company’s stock.

Avidity Biosciences Stock Up 6.3 %

Avidity Biosciences stock opened at $24.16 on Tuesday. Avidity Biosciences, Inc. has a 12-month low of $4.82 and a 12-month high of $27.66. The company has a market capitalization of $1.93 billion, a PE ratio of -8.33 and a beta of 0.77. The firm’s fifty day moving average is $21.27 and its 200 day moving average is $12.84.

Avidity Biosciences (NASDAQ:RNA) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.25). Avidity Biosciences had a negative return on equity of 39.74% and a negative net margin of 2,219.87%. The company had revenue of $2.19 million for the quarter, compared to the consensus estimate of $32.08 million. Sell-side analysts expect that Avidity Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Avidity Biosciences Profile

Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.